Mecwins installs state-of-the-art AVAC platform at Destina Genomica

From February 16th to 17th, the Mecwins team was on site at Destina Genomica’s laboratories to install a new biosensing AVAC platform. This platform represents a crucial step in the development of an important project that has secured over 1.3 million euros in funding through the Public-Private Partnership program.

In collaboration with Destina Genómica SL, the Foundation for Biomedical Research of the Ramon y Cajal University Hospital and the Advanced Photonic & Biofunctional Materials Group of the UAM (Universidad Autónoma de Madrid), Mecwins is leading the development of a state-of-the-art sensor for the diagnosis and prognosis of Alzheimer’s disease (CPP2021-008902, ALZHEIMER-PROmiR-SENSOR).

Titled “Development of a sensor for the simultaneous detection of proteins and micro RNAs for the diagnosis and prognosis of Alzheimer’s disease,” the project represents a major advancement in the field of Alzheimer’s research and has the potential to revolutionize the way we detect and treat this debilitating disease.

Having successfully completed the installation, the team looks forward to returning to Granada to continue the progress of this groundbreaking project.